Physician profile
Marissa Kramer
NPI 1700561321
$1,409.66
in general payments reported to CMS, 2019-2025
17 companies · $866 in 2025
The $866 reported for 2025 was more than what 82% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $15.52 · 2024: $528 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,409.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $201.43 | 2024-2025 | |
| Lilly USA, LLC | $184.38 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Sequel Med Tech, LLC | $149.27 | 2025 | Twiist |
| Novo Nordisk INC | $127.65 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $123.73 | 2023-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $75.68 | 2024-2025 | Shingrix, Arexvy, Bexsero |
| Astrazeneca Pharmaceuticals LP | $75.52 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.70 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $71.35 | 2024-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $67.38 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $63.79 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $53.15 | 2024-2025 | Eliquis |
| Pfizer INC. | $51.28 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $37.04 | 2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.40 | 2025 | Jardiance |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19.14 | 2025 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $15.77 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.